Report Information Asia-Pacific Cancer Biomarker Testing Market Research by Type, by Testing Type, by Region Forecast to 2032

Description

List of Tables

Report Information Asia-Pacific Cancer Biomarker Testing Market Research by Type (Product and Services), by Testing Type (Single Gene Testing and Multiple Gene Testing), by Region (China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan) Forecast to 2032

Market Overview

Asia-Pacific Cancer It is anticipated that the Biomarker Testing Market will experience a significant compound annual growth rate (CAGR) of 12.58% during the review period.

The term "cancer biomarker testing" denotes the detection of biological markers, such as molecules or genes, in blood, tissues, or other physiological fluids to ascertain the presence, progression, or risk of cancer. Early identification, diagnosis, prognosis, and treatment selection can be facilitated by these biomarkers, which can offer critical insights into the genetic, genomic, and cellular characteristics of a tumour. Biomarker testing enables clinicians to comprehend the distinctive characteristics of a patient's malignancy, thereby enabling the development of more personalised treatment strategies. Biomarkers in cancer may be genetic (e.g., DNA mutations), proteomic (protein-related), or epigenetic. Next-generation sequencing (NGS), polymerase chain reaction (PCR), and immunohistochemistry comprise the testing procedures. Cancer biomarker testing is particularly beneficial for targeted therapies and immunotherapies, as it identifies individuals who are most likely to benefit from specific treatments based on the genetic composition of their tumours.. Biomarker testing contributes to the monitoring of disease development, the detection of recurrences, and the evaluation of treatment response, in addition to guiding medication. Biomarker testing becomes an increasingly critical instrument for enhancing cancer care outcomes and fostering precision medicine as cancer research advances.

Market Segmentation

The Asia-Pacific cancer biomarker testing market has been segmented into product and services based on type. The services segment is the fastest-growing segment during the forecast period (2024-2032), while the product segment held the greatest market share in 2023.

The Asia-Pacific cancer biomarker testing market has been segmented into single gene testing and multiple gene testing, based on the type of testing. In 2023, the multiple gene testing segment occupied the largest market share and is expected to experience the most rapid growth during the forecast period (2024-2032).

The global Asia-Pacific Cancer biomarker testing market has been segmented into the following countries: China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan. The India segment is the fastest-growing segment during the forecast period (2024-2032), while the China segment held the largest market share in 2023.

Major Players

The foremost market participants are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences, Qiagen N.V., and Oxford Nanopore Technologies Plc.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research Data Flow:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Type
3.8 DATA MODELING
- 3.8.1 microeconomic factor analysis:
- 3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Growing Prevalence of Cancer
- 4.2.2 Rising Demand for Early Detection
- 4.2.3 Partnership Associated With Cancer Biomarker Testing Products
4.3 RESTRAINTS
- 4.3.1 Limited Access to Healthcare Infrastructure
- 4.3.2 High Cost OF Cancer Biomarker Testing
4.4 OPPORTUNITY
- 4.4.1 Growing Geriatric Population
- 4.4.2 Growing investment Associated with Cancer Biomarker Diagnosis
- 4.4.3 Ongoing Research to Develop Biomarker for Early Detection

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 Bargaining Power of Suppliers
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET
5.3 QUALITATIVE ANALYSIS FOR PROGRESSION & RESISTANCE PROFILING FOR CANCER
5.4 QUALITATIVE DATA ON THE TYPES OF DIGITAL SERVICES UTILIZED IN CANCER BIOMARKER TESTING
5.5 QUALITATIVE DATA ON TREATMENT SELECTION FOR TYPE OF CANCERS

6 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TYPE

6.1 INTRODUCTION
6.2 PRODUCTS
6.3 SERVICES

7 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE

7.1 INTRODUCTION
7.2 SINGLE GENE TESTING
7.3 MULTIPLE GENE TESTING

8 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY

8.1 OVERVIEW
- 8.1.1 India
- 8.1.2 Australia
- 8.1.3 Hong Kong
- 8.1.4 Taiwan
- 8.1.5 China
- 8.1.6 South Korea
- 8.1.7 Thailand
- 8.1.8 Japan
- 8.1.9 Singapore
- 8.1.10 New Zealand

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS, 2023
9.3 COMPETITOR DASHBOARD
9.4 PUBLIC PLAYERS STOCK SUMMARY
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.1.1 PRODUCT LAUNCH
- 9.1.2 PRODUCT APPROVAL
- 9.1.3 COLLABORATION

10 COMPANY PROFILES

10.1 F. HOFFMANN-LA ROCHE LTD.
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
10.2 THERMO FISHER SCIENTIFIC INC.
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
10.3 BIO-RAD LABORATORIES, INC.
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 SWOT ANALYSIS
- 10.3.6 KEY STRATEGIES
10.4 ILLUMINA, INC.
- 10.4.1 COMPANY OVERVIEw
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGIES
10.5 PACIFIC BIOSCIENCES
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 fINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERed
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 KEY STRATEGIES
10.6 GENEWIZ, INC.
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 SERVICES OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 SWOT ANALYSIS
- 10.6.6 KEY STRATEGIES
10.7 QIAGEN N.V.
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERed
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT ANALYSIS
- 10.7.6 KEY STRATEGIES
10.8 OXFORD NANOPORE TECHNOLOGIES PLC
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 MGI TECH CO., LTD.
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 KEY STRATEGIES
10.10 BIOSERVE
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 SERVICES OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 KEY STRATEGIES

11 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR PRODUCTS, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SERVICES, BY VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 5 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR PRODUCTS, BY COUNTRY, 2019-2032 (USD THOUSAND)
TABLE 6 GLOBAL MARINE COLLAGEN MARKET, FOR SERVICES, BY COUNTRY, 2019-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 9 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, BY TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 11 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 13 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, BY COUNTRY, 2019-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY COUNTRY, 2019-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY, 2019-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 17 INDIA CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 18 INDIA CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 19 INDIA CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 20 INDIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 21 INDIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 22 INDIA CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 23 INDIA CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 24 INDIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 25 INDIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 26 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 27 AUSTRALIA CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 28 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 29 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 30 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 31 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 32 AUSTRALIA CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 33 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 34 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 35 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 36 HONG KONG CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 37 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 38 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 39 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 40 HONG KONG CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 41 HONG KONG CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 42 HONG KONG CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 43 HONG KONG CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 44 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 45 TAIWAN CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 46 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 47 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 48 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 49 TAIWAN CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 50 TAIWAN CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 51 TAIWAN CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019-2032 (USD THOUSAND)
TABLE 52 TAIWAN CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019-2032
TABLE 53 CHINA: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 54 CHINA: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019-2032 (USD THOUSAND)
TABLE 55 CHINA: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019-2032 (NO. OF TESTS)
TABLE 56 CHINA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 57 CHINA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (NO. OF TESTS)
TABLE 58 CHINA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 59 CHINA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (NO. OF TESTS)
TABLE 60 CHINA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 61 CHINA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 62 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 63 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019-2032 (USD THOUSAND)
TABLE 64 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019-2032 (NO. OF TESTS)
TABLE 65 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 66 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (NO. OF TESTS)
TABLE 67 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 68 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (NO. OF TESTS)
TABLE 69 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 70 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 71 THAILAND: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 72 THAILAND: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019-2032 (USD THOUSAND)
TABLE 73 THAILAND: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019-2032 (NO. OF TESTS)
TABLE 74 THAILAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 75 THAILAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (NO. OF TESTS)
TABLE 76 THAILAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 77 THAILAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (NO. OF TESTS)
TABLE 78 THAILAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 79 THAILAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 80 JAPAN: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 81 JAPAN: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019-2032 (USD THOUSAND)
TABLE 82 JAPAN: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019-2032 (NO. OF TESTS)
TABLE 83 JAPAN: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 84 JAPAN: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (NO. OF TESTS)
TABLE 85 JAPAN: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 86 JAPAN: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (NO. OF TESTS)
TABLE 87 JAPAN: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 88 JAPAN: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 89 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 90 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019-2032 (USD THOUSAND)
TABLE 91 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019-2032 (NO. OF TESTS)
TABLE 92 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 93 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (NO. OF TESTS)
TABLE 94 SINGAPORE: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 95 SINGAPORE: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (NO. OF TESTS)
TABLE 96 SINGAPORE: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 97 SINGAPORE: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 98 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 99 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019-2032 (USD THOUSAND)
TABLE 100 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019-2032 (NO. OF TESTS)
TABLE 101 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (USD THOUSAND)
TABLE 102 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019-2032 (NO. OF TESTS)
TABLE 103 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 104 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019-2032 (NO. OF TESTS)
TABLE 105 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 106 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019-2032 (USD THOUSAND)
TABLE 107 PRODUCT LAUNCH
TABLE 108 PRODUCT APPROVAL
TABLE 109 COLLABORATION
TABLE 110 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 111 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 112 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 113 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
TABLE 114 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 115 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS
TABLE 116 ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 117 ILLUMINA, INC.: KEY DEVELOPMENTS
TABLE 118 PACIFIC BIOSCIENCES: PRODUCTS OFFERED
TABLE 119 PACIFIC BIOSCIENCES: PRODUCTS OFFERED
TABLE 120 GENEWIZ, INC.: SERVICE OFFERED
TABLE 121 QIAGEN N.V.: PRODUCT OFFERED
TABLE 122 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS OFFERED
TABLE 123 MGI TECH CO., LTD.: PRODUCT OFFERED
TABLE 124 BIOSERVE: SERVICE OFFERED

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET: STRUCTURE
FIGURE 2 ASIA PACIFIC CANCER BIOMARKER TESTING MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET
FIGURE 6 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSAND)
FIGURE 7 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TYPE, 2023 & 2032 (USD THOUSAND)
FIGURE 8 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET SHARE (%), BY TYPE, 2023
FIGURE 9 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, TESTING TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSAND)
FIGURE 10 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2023 & 2032 (USD THOUSAND)
FIGURE 11 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET SHARE (%), BY TESTING TYPE, 2023
FIGURE 12 ASIA-PACIFIC MARKET ANALYSIS: CANCER BIOMARKER TESTING MARKET, 2019-2032 (USD THOUSAND)
FIGURE 13 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY, 2023 & 2032 (USD THOUSAND)
FIGURE 14 ASIA-PACIFIC CANCER BIOMARKER TESTING SHARE (%), BY COUNTRY, 2023
FIGURE 15 ASIA PACIFIC CANCER BIOMARKER TESTING MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
FIGURE 16 COMPETITOR DASHBOARD: ASIA PACIFIC CANCER BIOMARKER TESTING MARKET
FIGURE 17 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
FIGURE 19 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 21 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS
FIGURE 23 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 PACIFIC BIOSCIENCES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 GENEWIZ, INC.: SWOT ANALYSIS
FIGURE 26 QIAGEN N.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 QIAGEN N.V.: SWOT ANALYSIS
FIGURE 28 OXFORD NANOPORE TECHNOLOGIES PLC: FINANCIAL OVERVIEW SNAPSHOT